20-23 June, 2018 Barcelona
1-O | Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors | Funda Meric-Bernstam | Received |
1-LB | Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH) | Mia Chen | Received |
2-LB | Overall survival results from a phase III trial of trifluridine/tipiracil vs. placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS) | Josep Tabernero | Received |
2-PD | A phase I/II trial of hafnium oxide nanoparticles activated by radiotherapy in hepatocellular carcinoma and liver metastasis | Angelo Cho | Received |
3-PD | Comparison of prognosis after hepatic resection of hepatocellular carcinoma between intermediate stage tumor and early stage tumor | Junichi Arita | Received |
3-P | Targeted-sequencing and comprehensive molecular profiling of gastric signet ring cell carcinoma | Jia Wei | Received |
4-P | MicroRNAs and CDH1 regulation in intestinal-type gastric cancer | chiara molinari | Received |
5-O | A multicentre, prospective clinical evaluation study for analyzing RAS mutational status utilizing plasma circulating tumor DNA in patients with metastatic colorectal cancer | Yoshinori Kagawa | Received |
5-P | Retrospective analysis of the frequency of the ALK translocation obtained by immunohistochemistry in gastric adenocarcinomas in a single Costa Rican hospital | Luis Corrales-Rodriguez | Received |
5-PD | Post-Operative Venous Thromboembolism and Mortality in Patients with Pancreatic Cancer Surgery | Kaushal Majmudar | Received |
6-PD | Characterizations of DNA copy number variations and spatio-temporal intra tumor heterogeneity in liver metastasis from colorectal cancer patients | Maud Marques | Received |
6-P | Personalization of treatment for patients with stomach cancer using molecular genetic markers | Igor Bykov | Received |
7-O | Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cetiri: Final results and translational analyses of the CRICKET study by GONO | Daniele Rossini | Received |
8-P | Treatment decisions in adolescents and young adults with gastric cancer in North Estonia Medical Centre from 2007-2016 | Mari Lhmus | Received |
8-PD | Molecular characterization of immune microenvironment in colorectal cancers with microsatellite instability by digital RNA counting | Mirella Giordano | Received |
9-PD | Emergence of KRAS mutation may play a major role in the secondary resistance to EGFR blockade | Takeshi Yamada | Received |
9-P | Epidemiology and overall survival of gastric carcinoma patients (about 210 cases) experience of medical oncology department of CHU Hassan II Fez | hayat erraichi | Received |
10-P | Berberine inhibits the migration and invasion via AMPK/HNF4a pathway in gastric cancer | Qian Hu | Received |
10-PD | REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis | Kohei Shitara | Received |
11-P | Estrone is a marker of the pre-metastatic niche in patients with stomach cancer | Oleg Kit | Received |
11-PD | SAPPHIRE: A randomized phase II study of oxaliplatin discontinuation after 6 cycles of mFOLFOX6 panitumumab therapy in patients with colorectal cancer: Final analysis of efficacy and safety results | Tomoko Miura | Received |
11-O | Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC) | Philippe Merle | Received |
12-PD | Early tumour shrinkage (ETS) and its impact on tumour-related symptoms in patients with previously untreated RAS wild-type metastatic colorectal cancer (mCRC): A retrospective analysis of three panitumumab studies | Katarina Gluic | Received |
12-O | Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice: Final analysis from the prospective, observational CORRELATE study | Katarina Gluic | Received |
13-PD | Usefulness of colonic tattooing using ICG in patients with colorectal tumors | Jae Ho Park | Received |
13-O | Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer (mCRC): Preliminary results from the phase IIIb, international, open-label, early-access PRECONNECT study | Sarah Novack | Received |
13-P | Redox forms of glutathione mark the aggressiveness of stomach cancer | Irina Goroshinskaya | Received |
14-P | Diagnostic and therapeutic efficacy of endoscopic enucleation for subepithelial tumors originating from muscularis propria layer | byoung wook bang | Received |
14-O | Regorafenib Dose Optimization Study (ReDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC) An ACCRU Network study | Tanios Bekaii-Saab | Received |
15-P | Patient derived xenografts from American minority gastric cancer patients | Sam Wang | Received |
16-PD | Safety of self-expandable metal stents (SEMS) or emergency surgery for acute colonic obstruction in metastatic colon cancer patients treated with bevacizumab | Vilma Pacheco-Barcia | Received |
16-O | First-line FOLFOX plus panitumumab (pan) followed by 5-FU/LV plus pan or single-agent pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study | Filippo Pietrantonio | Received |
17-O | FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: Final results of the phase II randomized MOMA trial by GONO | Federica Marmorino | Received |
17-P | Overall survival of patients with HCC treated with sorafenib versus patients treated with supportive therapy in evidence in Oncology Cabinet of Municipal Hospital of Pascani in session 2013-2018 | Elena-Carmen Bosteanu | Received |
17-PD | Clinical and molecular determinants of extrahepatic disease progression (ePD) in initially unresectable, liver-limited metastatic colorectal cancer (mCRC) | Elena Ongaro | Received |
18-PD | Comparing survival in left-sided and right-sided colorectal carcinoma: A Belgian population-based study | Katleen Janssens | Received |
19-P | Clinic-pathological pattern of hepatocellular carcinoma (HCC) in Egypt | Ahmed Gaballah | Received |
19-PD | RMB (RENCA Macrobead) therapy in advanced mCRC: Phase IIb preliminary multi-site survival findings; correlation & combination with Phase I and IIa data including imaging and lab profiles U.S.FDA BB-IND 10091 | Angelica Nazarian | Received |
20-P | Immunohistochemical study of KRAS, NRAS, BRAF and MSI phenotype in small bowel adenocarcinoma | Vasiliki Michalaki | Received |
21-P | Molecular profiling of gastrointestinal cancer | PANAGIOTIS PARSONIDIS | Received |
22-O | Phase II study evaluating trifluridine/tipiracilbevacizumab and capecitabinebevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis | Eric Van Cutsem | Received |
23-P | Gastrointestinal stromal tumours: Retrospective review of an institution | Helena Magalhaes | Received |
24-P | Varying distribution of tissue plasminogen activators in gastrointestinal adenocarcinoma | Oleg Kit | Received |
26-P | Tumor-associated universal inhibitors and free plasmin in adenocarcinoma of stomach and pancreatic head | Elena Frantsiyants | Received |
27-P | Polymer hydrogels as innovative carriers for anticancer therapy | Magdalena K&281;dzierska | Received |
28-P | Lipoxin A4 inhibits the paracrine of Nodal in CAFs by suppressing FPRL1/ROS/NF-?B signaling to attenuate invasion and metastasis of gallbladder carcinoma | Yu Shi | Received |
28-O | Long-term effect of peripheral sensory neuropathy (PSN) of 3 or 6 months oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: ACHIEVE as part of the IDEA collaboration | Shintaro Takeuchi | Received |
30-P | Epidemiological profile and factors associated with mortality among patients with gastrointestinal cancers in a Haitian cancer program | Joseph Jr Bernard | Received |
31-P | Morbidity trends for ed gastrointestinal cancers in Poland and the costs of treatment | Miroslaw Jarosz | Received |
33-P | Longitudinal assessment of neutrophil-to-lymphocyte ratio (NLR) from diagnosis until death reveals a biphasic trend in metastatic pancreatic adenocarcinoma patients | Cristina Morelli | Received |
35-P | Hepatic stellate cells (HSCs) activating HSF1-mediated COMP secretion promote liver metastasis of pancreatic cancer through CD36/AKT/FOXM1 signaling | Liankang Sun | Received |
36-P | High proliferation is independently associated with disease progression in metastatic pancreatic adenocarcinoma | Sally Temraz | Received |
40-P | Biochemical and radiological inflammatory markers in oesophageal squamous cell carcinoma treated with radical chemoradiation | Khin Ni Sann | Received |
41-P | Prognostic impact of C-reactive protein / albumin ratio in locally advanced esophageal cancer | Joana Simes | Received |
42-P | Definitive chemoradiation in esophageal squamous-cell carcinoma: Carboplatin/paclitaxel versus cisplatin/5-FU | Nuno Tavares | Received |
43-P | Oncologic outcomes of elderly patients with localized esophageal cancer who underwent curative surgery compared with younger patients | Hyun Ho Choi | Received |
44-P | Long term survival in advanced esophageal cancer, treated with a French modality of hypofractionated radiotherapy chemotherapy with or without surgery, the experience at the Instituto Nacional de Cancerología, México | Jesus Zamora Moreno | Received |
45-P | Analysis of global factors associated with survival in esophageal squamous cell carcinoma: Our experience at Ramon y Cajal Hospital | Arantzazu Barquín García | Received |
48-P | Neoadjuvant chemotherapy for locally advanced squamous cell carcinoma of esophagus: Clinical profile and outcomes from tertiary care cancer centre | Naveen kumar | Received |
52-P | A phase 3 study of chemotherapy pembrolizumab versus chemotherapy placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590 | Ken Kato | Received |
53-P | Pre-treatment peripheral neutrophil-lymphocyte ratio as a prognostic factor in gastric cancer | Ahmed Gaballah | Received |
54-P | Predicting HER2 status in esophagogastric cancer: Development and validation of an easy-to-use nomogram | IRENE PECORA | Received |
55-P | Prolonged overall survival of metastatic gastric cancer patients with BRCA germline mutations | Naama Halpern | Received |
56-P | Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are independent prognostic factors for overall survival in Hispanic patients with gastric adenocarcinoma | Allan Ramos-Esquivel | Received |
57-P | Predicting survival benefit of capecitabine plus cisplatin in patients with metastatic gastric cancer patients using quantitative proteomics | Fabiola Cecchi | Received |
58-P | The prognostic value of systemic inflammatory factors in patients with HER2-positive metastatic gastric cancer | Nieves Martinez Lago | Received |
60-P | Comparison of efficacy and safety between redo-endoscopic treatment and surgery for recurrent gastric neoplasms at the scar of prior endoscopic submucosal dissection | Do Hoon Kim | Received |
63-P | The clinical outcomes and the pathogenetic background of gastric MALT lymphoma in Korea | SANG MIN LEE | Received |
64-P | Early outcomes of a pilot study of neoadjuvant chemotherapy with S-1 plus oxaliplatin at dose of 130mg/m2 (nacG-SOX130) in stage III gastric cancer | Sayuri Konishi | Received |
65-P | Patterns of care and clinical outcomes for gastric and gastro-oesophageal cancers in South Australian population: Initial results of a state-wide audit | Nazim Abbas | Received |
67-P | Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: A retrospective study | Takatsugu Ogata | Received |
69-P | Associated factors with overlooked multiple synchronous gastric epithelial neoplasia | Cheol Woong Choi | Received |
72-P | Is the prognostic effect of etiologies in patients with gastric cardia cancer during a recent decade of Korea? | Suyun Oh | Received |
73-P | Prognostic factors for gastric cancer after curative gastrectomy | Sarra Karrit | Received |
74-P | Outcome and prognostic factors of gastric cancer in Tunisia | Sarra Karrit | Received |
78-P | Management, outcome and prognostic factors of metastatic gastric cancer | Sarra Karrit | Received |
79-P | Efficacy and safety of nivolumab monotherapy for metastatic gastric cancer | Kohei Akiyoshi | Received |
80-P | Gastric cancer in young patients under the age of 45 years old: A comparative study with older patients | Sarra Karrit | Received |
81-P | Early experience on the histopathological response to perioperative docetaxel, oxaliplatin and 5-FU/Sodium levofolinate (FLOT) for patients with resectable gastric adenocarcinoma when compared to cisplatin/5-fluorouracil (CF) | Ana Rolo | Received |
82-P | Neoadjuvant chemotherapy in gastric cancer | Adda Bounedjar | Received |
85-P | The impact of the difference in total diameter of metastatic tumor as a prognostic factor for advanced gastric cancer treated with systemic chemotherapy | Yusuke Sasaki | Received |
86-P | Treatment and testing patterns among patients with HER2 advanced/metastatic gastric, esophageal or gastroesophageal junction (GEJ) adenocarcinoma in the United States | Lisa Hess | Received |
88-P | Genetic polymorphisms and PG1/PG2 and G17 levels can predict gastric carcinoids in autoimmune atrophic chronic gastritis patients | Renato Cannizzaro | Received |
89-P | Gastric cancer in Lynch Syndrome: Are precancerous conditions co- risk factors? | Renato Cannizzaro | Received |
90-P | Ethnic and racial disparities among young patients with noncardia gastric cancer | Matthew Porembka | Received |
95-P | A randomized clinical trial of apatinib on an intermittent versus continuous dosing schedule in combination with docetaxel for advanced gastric cancer in second-line setting | Xianmeng Wu | Received |
96-P | A phase 3 study of chemotherapy pembrolizumab vs chemotherapy placebo as neoadjuvant/adjuvant treatment for patients with gastric or gastroesophageal junction (G/GEJ) cancer: KEYNOTE-585 | Yung-Jue Bang | Received |
97-P | SIRT therapy with Yttrium-90 resin microspheres in patients with liver cirrhosis Child Pugh B7-9 and unresectable nonmetastatic hepatocellular cancer | Jan Eick | Received |
98-P | Treatment patterns and costs of care for patients diagnosed with hepatocellular carcinoma (HCC) in the United States (U.S.) | LISA HESS | Received |
101-P | HEPANOVA: A phase 2 trial of tumor treating fields concomitant with sorafenib for advanced hepatocellular carcinoma | Hugo Siedlecki | Received |
102-P | A retrospective review of neutrophil-lymphocyte ratio as a predictive prognostic marker in upper gastrointestinal cancers in three UK hospitals over a nine year period | Nicholas Wreglesworth | Received |
103-P | The prospective multicenter study of relation between 5-HIAA / substance P plasma concentration transition and nausea/vomiting in patients with gastrointestinal cancer receiving moderately emetogenic chemotherapy | Tetsuhito Muranaka | Received |
105-P | Clinical outcomes and toxicity of chemoradiation with IMRT for anal cancer | João Fonseca | Received |
109-P | Detection and management of hyperglycaemia in oncology patients receiving systemic anti-cancer therapy | Laura Morrison | Received |
110-P | Squamous cell carcinoma of the anal canal and the results of radical treatment with intensity-modulated radiotherapy | Irena Oblak | Received |
114-P | The prognostic values of tumor characteristics and clinical factors of neuroendocrine tumors: Two centers experience | Banu Ozturk | Received |
116-P | A long-term analysis of imatinib palliative treatment in gastrointestinal stromal tumors | Isabel Domingues | Received |
117-P | 30-day mortality associated with systemic anti-cancer therapy (SACT) in gastrointestinal malignancies: The Christie experience | Francisca Elena Marti Marti | Received |
118-P | Chemoradiation for anal canal carcinoma in a comprehensive cancer center: Retrospective cohort study | João Dias | Received |
119-P | The feasibility study of short hydration with oral rehydration therapy in chemotherapy with cisplatin plus gemcitabine for biliary tract cancer (KHBO-1302) | Tatsuya Ioka | Received |
121-P | Impaired quality of life of caregivers of patients with gastrointestinal cancer undergoing palliative chemotherapy | Nobumichi Takeuchi | Received |
123-P | Quality of life by Karnofsky index in patients with gastrointestinal cancer subject to parenteral nutritional therapy | TICIANA MARIA RANGEL DE PAULA PESSOA | Received |
124-P | De novo malignancies in patients after liver transplantation: A single centre experience | Klara Chmelova | Received |
125-P | Laparoscopic liver resection for tumors in proximity to major vasculature and the impact of neo-adjuvant systemic therapy | Mathieu DHondt | Received |
126-P | Impact of revision surgery timing on overall survival in incidentally detected gall bladder cancer: An experience from tertiary care centre of Northern India | Ashutosh Mishra | Received |
127-P | Impact of lymph node positivity on overall survival in operable gall bladder cancer: An experience from tertiary cancer care centre from Northern India | Ashutosh Mishra | Received |
128-P | Surgical resection of primary tumor site is prolonged survival in metastatic pancreatic neuroendocrine carcinoma | Tingting Feng | Received |
129-P | Comparing efficacy of 1-L Peg-Asc with prucalopride versus 2-L Peg-Asc for bowel preparation | Se Hyun Jang | Received |
130-P | A phase I/II Trial of CRISPR-Cas9-mediated PD-1 knockout Epstein-Barr virus cytotoxic lymphocytes (EBV-CTLs) for advanced stage EBV associated malignancies | Jia Wei | Received |
131-P | Endoscopic detachable auxiliary manipulator in endoscopic submucosal dissection: Animal model studY | Han Jo Jeon | Received |
132-P | Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabineplacebo versus gemcitabineevofosfamide and identifies candidate targets | Valeriy Domenyuk | Received |
133-P | The use of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and CA 19-9 as prognostic markers for locally advanced pancreatic cancer | Meabh McNulty | Received |
136-P | Timed-flat infusion (TFI) 5-fluorouracil with irinotecan and oxaliplatin in pancreatic adenocarcinomas: A single institution experience with FIr/FOx regimen | Alessandro Parisi | Received |
137-P | Intraperitoneal chemotherapy for pancreatic cancer with peritoneal metastases: A single center retrospective analysis of 25 patients | Yasushi Tsuji | Received |
138-P | Predictive factors for early relapse and survival in resected pancreatic cancer: A single institution experience | Cristina Saavedra | Received |
139-P | HGCSG 1403: Phase I trial of oxaliplatin / irinotecan / S-1 (OX-IRIS) as first line chemotherapy for unresectable pancreatic cancer | Satoshi Yuki | Received |
141-P | PanCO: An open-label, single-arm pilot study of Oncosil in patients with unresectable locally advanced pancreatic adenocarcinoma in combination with FOLFIRINOX or gemcitabinenab-paclitaxel chemotherapies | Thomas Maher | Received |
142-P | Updated results of biweekly gemcitabine/nab-paclitaxel as first-line treatment for advanced pancreatic cancer | Maria Drizou | Received |
143-P | Safety of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer patients presenting with hyperbilirubinemia secondary to bile duct obstruction | Mitsuhito Sasaki | Received |
147-P | Use of gemcitabine and nab-paclitaxel as a third-line treatment following failure of first line gemcitabine for advanced pancreatic adenocarcinoma | Meabh McNulty | Received |
149-P | Risk factors and epidemiological features of pancreatic cancer in Iran | Akram Pourshams | Received |
154-P | Real life triplet FIr/FOx chemotherapy in first line metastatic pancreatic ductal adenocarcinoma: Recommended schedule for expected activity and safety and phase II study | Gemma Bruera | Received |
156-P | Effectiveness and costs of FOLFIRINOX in the treatment of advanced pancreatic cancer in a Portuguese oncology center | Helena Magalhaes | Received |
157-P | Gemcitabine/nabpaclitaxel efficacy in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma | Vasiliki Michalaki | Received |
158-P | Correlation of neutrophil lymphocyte ratio, platelet lymphocyte ratio and rate of change of CA 19-9 in predicting outcome for metastatic pancreatic cancer | Adarsh Das | Received |
159-P | Analysis of early tumor shrinkage and depth of response in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX or gemcitabine nab-paclitaxel | Vivaldi Caterina | Received |
160-P | Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice | Gerarrd Carot-Sans | Received |
161-P | Folfirinox versus gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer: a single-center cohort study | IN RAE CHO | Received |
162-P | Second line in pancreatic cancer: Resuming our experience and looking for prognostic factors | Beatriz Antón | Received |
163-P | Observational study of comparative effectiveness of nab-paclitaxel plus gemcitabine vs gemcitabine plus cisplatin or gemcitabine alone for the first-line treatment of metastatic pancreatic adenocarcinoma in the University Hospital Centre Zagreb | Juraj Prejac | Received |
164-P | Gemcitabine plus nab-paclitaxel versus modified FOLFIRINOX as first line chemotherapy in metastatic pancreatic cancer: A comparison of toxicity and survival | Vilma Pacheco-Barcia | Received |
165-P | Clinical outcomes for modified FOLFIRINOX chemotherapy for pancreatic cancer | DANIEL HOLYOAKE | Received |
168-P | Multiple dose pharmacokinetics of erlotinib when combined with gastric acid reducing agents: A comparison with a physiologically based pharmacokinetic model | Azra Sahmanovic Hrgovcic | Received |
170-P | Management of patients with unresectable HCC: A simulation-based assessment of medical oncologists practice choices | Emily Meier | Received |
171-P | Analysis of echoendoscopic punctures of a solid pancreatic lesions in a private institution in Brazil | TICIANA MARIA RANGEL DE PAULA PESSOA | Received |
172-P | Treatment modalities and prognostic factors of pancreatic cancer: A retrospective study | Imtinane Belaid | Received |
175-P | Clinical implication of inflammation markers for identifying radiotherapy candidates in inoperable locally advanced pancreas cancer | won kyung cho | Received |
176-P | Analysis of various clinical and pathological factors affecting survival in patients diagnosed with pancreatic adenocarcinoma: Single institute study | Ahmed Nagy | Received |
177-P | Epidemiology of pancreatic cancer | Imtinane Belaid | Received |
180-P | Neo-adjuvant FOLFIRINOX in borderline-resectable/locally advanced pancreatic adenocarcinoma: An updated analysis | Sally Temraz | Received |
181-P | Pancreatic head resections: Impact factors, perioperative morbidity, mortality and long-term survival | Bojan ILIJEVEC | Received |
184-P | CanStem 111P Trial: A Phase 3 Study of Napabucasin (NAPA) Plus Nab-Paclitaxel (nPTX) With Gemcitabine (Gem) in Adult Patients With Metastatic Pancreatic Adenocarcinoma (mPDAC) | Natalie Johnson | Received |
185-P | PANOVA-3: A phase 3 study of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma | Hugo Siedlecki | Received |
187-P | Erythrocyte membrane fatty acids as the potential biomarkers for detection of early-stage and progression of colorectal cancer | Margarita Kruchinina | Received |
189-P | Retinoic acid-induced 2 (RAI2) is a potential tumor suppressor and RAI2 promoter methylation is a poor prognostic marker in colorectal cancer | Wenji Yan | Received |
191-P | Combined analysis of KRAS, NRAS, BRAF mutations and mismatch repair deficiency testing in Indian patients with metastatic colorectal carcinoma: A single centre experience | TANVI SOOD | Received |
193-P | RAS status in Algerian metastatic colorectal cancer | Assia Bensalem | Received |
194-P | Transcribed ultraconserved regions Uc160 and Uc346 in colon cancer progression | Foteinos- Ioannis Dimitrakopoulos | Received |
195-P | Cost of illness for colorectal cancer at low middle income countries Egypt case | Abdalla Abotaleb | Received |
197-P | Repurposing ponatinib for the treatment of colorectal cancer | Rodney Luwor | Received |
199-P | Colorectal cancer screening in Flanders: Advances in personalised screening | Wessel van de Veerdonk | Received |
201-P | Evaluation of the prognostic value of lymph-node ratio in patients with colon cancer in the oxaliplatin era | Darragh Connell | Received |
203-P | Survival and prognostic factors of non metastatic rectal adenocarcinoma: Analytic multifactor review of 91 cases | Khadija Darif | Received |
204-P | Prognostic value of neo-adjuvant treatment in localized rectal cancer about 78 cases | Khadija khadija | Received |
205-P | Preoperative short course of radiotherapy in ed high risk patients | Monica Caro Gallarin | Received |
206-P | Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and individual limiting toxicity syndromes prediction by pharmacogenomic biomarkers | Gemma Bruera | Received |
208-P | Autophagy (A) related proteins evaluation represents an independent survival factor of colorectal cancer (CRC) patients (pts) | Michalis Karamouzis | Received |
209-P | P 53 abnormal expression might influence global outcome through EGFR modulation in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan cetuximab | Marco Puzzoni | Received |
210-P | Unexpected discordance in 5-year OS rates between Nx colon cancer patients and those in stages II plus III | Ivan Tonev | Received |
211-P | Serum angiogenesis associated proteins and clinical outcome in metastatic colorectal cancer patients receiving bevacizumab | Alessandro Passardi | Received |
212-P | CDX2 immunohistochemistry as a prognostic biomarker for colorectal cancer | Abiola Fatimilehin | Received |
213-P | An evaluation of the clinical utility of a panel of variants in DPYD and ENOSF1 for predicting common capecitabine related toxicities | Fotheringham Susan | Received |
214-P | Bevacizumab combined with 1st line chemotherapy in elderly patients with metastatic colorectal cancer: Are there good prognostic indicators? | Katarina Gluic | Received |
216-P | Primum non nocere: Screening patients for fluoropyrimidine-related toxicity risk: The most effective method | Michèle Boisdron-Celle | Received |
217-P | ABCG2 and TOP-1 as predictive biomarkers and targets for therapy in colon cancer | Nils Brnner | Received |
221-P | Regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer: The optimization of pharmacological costs | Jacopo Giuliani | Received |
223-P | NORTH/HGCSG1003: A phase II study evaluating the safety and efficacy of FOLFOX as adjuvant chemotherapy for patients with stage III colon cancer: Comparison with medical oncologists and surgeons | Satoshi Yuki | Received |
224-P | Analysis of clinical outcomes of two antiEGFR antibodies, cetuximab and panitumumab, in the 1st line chemotherapy of RAS wild metastatic colorectal cancer, by neutrophil-to-lymphocyte ratio (NLR) kinetics | Dai Manaka | Received |
225-P | The role of maintenance therapy in the first line treatment of metastatic colorectal cancer | Danila Gridnev | Received |
226-P | HGCSG 1301: A Multicenter, Double-Blind, Randomized control phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS/Bev second-line treatment | Michio Nakamura | Received |
227-P | Analysis of the benefit of the adjuvant chemotherapy in stage II colon cancer according to the presence of classic poor risk factors: Our experience in Ramon y Cajal Hospital | Cristina Saavedra | Received |
228-P | VOLTAGE: Multicenter phase Ib/II study of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy (CRT) with capecitabine in patients with locally advanced rectal cancer (LARC) | Hideaki Bando | Received |
230-P | Second line FOLFOX4 and bevacizumab for metastatic colorectal cancer: Real life efficacy and predictive factors | Renata Biernacka | Received |
231-P | Clinical significance of microsatellite instability in gender-dependent patients with right-sided colorectal cancer | Ji Hun Choi | Received |
232-P | Efficacy of adjuvant chemotherapy for elderly patients with colon cancer | Maria Villamayor | Received |
233-P | Trifluridine/ tipiracil vs regorafenib as salvage-line treatment in patients with metastatic colorectal cancer: A multicenter retrospective study | Hironaga Satake | Received |
234-P | Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC) | Mary Smith | Received |
235-P | Adjuvant chemotherapy for colorectal cancer using oxaliplatin induced irreversible sinusoidal obstruction syndrome | Keisuke Hara | Received |
236-P | Clinical and pathological features in colorectal cancer associated to Lynch syndrome | OLIVER HIGUERA | Received |
237-P | Development of a new clinical nomogram including velocity rate of disease progression to predict outcome in metastatic colorectal cancer patients treated with bevacizumab beyond progression: A subanalysis from tribe trial | Marco Stellato | Received |
238-P | Analysis of classical high risk factors in stage III colon cancer: Experience at University Hospital Ramon y Cajal (UHRyC) | Juan José Serrano Domingo | Received |
239-P | Impact of adding oxaliplatin to fluoropyrimidines in the adjuvant therapy in stage II in colon cancer: Experience in Ramon y Cajal Universitary Hospital | Roberto Martín Huertas | Received |
240-P | Benefit of the addition of oxaliplatin to 5-FU/leucovorin or capecitabine in adjuvant therapy for stage II/III colorectal cancer in elderly patients: Experience in Ramon y Cajal University Hospital. | Elena Corral de la Fuente | Received |
242-P | International prospective multi-center clinical trial with adherence to surgical and pathological quality measures: Influence of body mass index (BMI) on outcome in colon cancer | Mladjan Protic | Received |
243-P | Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who achieved a clinical benefit in response to first-line panitumumab plus chemotherapy | AKIHITO TSUJI | Received |
244-P | Dose finding phase Ib study of triplet plus cetuximab for patients with wild-type RAS gene metastatic colorectal cancer (TRICETSU study) | Hironaga Satake | Received |
246-P | Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients | Mercedes Martinez Villacampa | Received |
250-P | Capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer: Experience of the oncology department of the university hospital of Oran, Algeria | zoubida Behourah | Received |
251-P | The prognostic ad predictive value of primary tumor sidedness in the mCRC pts | Banu Ozturk | Received |
252-P | The evaluation of liver resection for colorectal cancer liver metastases | Masaichi Ogawa | Received |
253-P | A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) refractory to standard chemotherapy: APOLLON study | Masaru Iwata | Received |
256-P | Treatment efficacy and survival analysis of extremely elderly (80 years of age or older) patients with metastatic colorectal cancer: Single institute retrospective study | Yi-Hsin Liang | Received |
257-P | Improvement of metastatic colorectal cancer patient survival: a Single institution experience | Elisabetta Fenocchio | Received |
258-P | HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of cases of prior regorafenib | Satoshi Yuki | Received |
259-P | Variability of current global practice patterns in the management of metastatic colorectal cancer | Krista Marcello | Received |
260-P | Quality-of-life in patients with metastatic colorectal cancer (mCRC) treated with aflibercept and FOLFIRI: Interim results of the non-interventional AIO study QoLiTrap | Liliana Borsellino | Received |
261-P | HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of GERCOR index | Satoshi Yuki | Received |
262-P | Trial-level analysis of early tumor shrinkage and disease control rate as intermediate end points of first-line medical treatment in randomized studies of metastatic colorectal cancer | Giuseppe Colloca | Received |
264-P | HGCSG1401: A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer: Analysis of risk factors for liver dysfunction | Satoshi Yuki | Received |
265-P | Treatment choices in metastatic colorectal cancer according to sidedness and RAS/BRAF status: A national survey by the Brazilian Group of Gastrointestinal Tumors (GTG) | Renata Peixoto | Received |
266-P | Retrospective analysis from efficacy with trifluridine-tipiracil (TAS-102) in patients with metastatic colorectal cancer and possible clinical factors associated with a greater benefit: experience at seven hospitals | Jesús Miranda | Received |
267-P | The prognostic impact of sidedness in RAS wild-type colorectal cancer | Nuno Tavares | Received |
269-P | Dynamics of the monoclonal antibodies (MABs) treatment rate and mortality rate in patients with metastatic colorectal cancer (mCRC) in Russia from 2013 to 2016 | Mikhail Fedyanin | Received |
270-P | Association between duration of oxaliplatin-free interval and effect of reintroduction of oxaliplatin-containing chemotherapy in patients with metastatic colorectal cancer (mCRC) | Mikhail Fedyanin | Received |
271-P | Prognostic impact of K-RAS mutational status and primary tumour location in patients undergoing resection for colorectal cancer liver metastases: A METHEPAR analysis (multicentre study in Argentina) | Juan Manuel OConnor | Received |
272-P | Understanding of metastatic colorectal cancer (mCRC) in the real world: Initial results from a European survey on the unmet needs of patients living with metastatic colorectal cancer | Zorana Maravic | Received |
273-P | Recruitment for a survey on the unmet needs of patients living with metastatic colorectal cancer (mCRC): Lessons from a European study | Zorana Maravic | Received |
274-P | The clinical effectiveness and safety of re-induction oxaliplatin, irinotecan and fluorouracil (FOLFOXIRI regimen) for the treatment of metastatic colorectal cancer after two lines of chemotherapy (oxaliplatin- and irinotecan-based regimens) | Anastasia Mochalova | Received |
275-P | Selective internal radiation therapy (SIRT) with yttrium-90 microspheres and peri-procedural FOLFIRI/Irinotecan in pre-treated colorectal liver metastases patients: An analysis of outcomes from a UK Cancer Centre between 2009 and 2017 | Gregory Wilson | Received |
276-P | Raltitrexed as salvage therapy for metastatic colorectal cancer: A multicenter retrospective study | Ismael Ghanem | Received |
277-P | Real world data in colorectal cancer: A retrospective analysis of overall survival in metastatic colorectal cancer patients between 2011-2015 treated in Spain, preliminary results (RWD-ACROSS study) | Carles PERICAY | Received |
279-P | Effectiveness of TAS-102 in patients with metastatic colorectal cancer in a single comprehensive cancer center | Carolina Sales | Received |
281-P | The impact of primary tumor location in patients with resected colorectal liver metastasis | Vilma Pacheco-Barcia | Received |
282-P | RAS status in metastatic colorectal cancer: What is the relationship to epidemiological and anatomo-clinical factors? | mariam haffadi | Received |
283-P | Skin disorders and primary tumor location as a prognostic factor of cetuximab plus chemotherapy in the treatment of advanced colorectal cancer | Takada Shinya | Received |
284-P | Characteristics of colorectal cancer in the elderly patients about 60 cases | Hanane Fatima Zahra Aliane | Received |
285-P | Optimizing the use of EGFR antibodies across the continuum of care in mCRC: Effect of online education on clinician knowledge, competence and confidence | Emily Meier | Received |
286-P | Integrating a paradigm shift in the treatment of metastatic colorectal cancer: Effect of online CME on oncologists knowledge and competence | Emily Meier | Received |
287-P | Treatment based on tumor sidedness in mCRC: Effect of online education on clinician knowledge, competence and confidence | Emily Meier | Received |
288-P | Causes of death in a cohort of early stage colorectal cancer patients at a regional centre in Australia | Lisi Elizabeth Lim | Received |
289-P | Prognostic factors for early recurrences following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases | Naveeshini Nair Chandran | Received |
291-P | The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status | Pina Ziranu | Received |
292-P | A phase II study of dose-escalation of regorafenib for patients with previously treated metastatic colorectal cancer DEREGULATE study | Kiyotaka Kawaguchi | Received |
293-P | Comorbidities (CM) and potential impact in outcomes of advanced colorectal cancer patients (ACC) in Argentina: EVIREPRO real life program | Andres Jorge Schmilovich | Received |
294-P | Multicenter phase Ib/ II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study) | Takeshi Kato | Received |
295-P | A multicenter, multicohort, phase 2 study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer | Owen Murray | Received |
297-P | CanStem 303C Trial: A Phase 3 Study of Napabucasin (NAPA) in CombinationWith 5-Fluorouracil (5-FU), Leucovorin, and Irinotecan (FOLFIRI) in AdultPatients With Previously Treated Metastatic Colorectal Cancer (mCRC) | Natalie Johnson | Received |
299-P | Predictive factors of complete pathological response in operated patients with locally advanced rectal cancer after chemoradiotherapy neoadjuvant treatment in Peru | Rodrigo Motta | Received |
300-P | Predictive value of circulating tumor-derived DNA (ctDNA) in patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiotherapy (CT-RT): preliminary results | Paola Simona Ravenda | Received |
301-P | CRP / albumin ratio can be a predictor of response to neoadjuvant chemoradiotherapy (CRT) in rectal cancer | Tarkan Yetisyigit | Received |
302-P | Pathological complete response after chemoradiotherapy in locally advanced rectal cancer: Capecitabine or 5-fluorouracil? Which is better? | Xavier Hernández-Yague | Received |
303-P | Food intake and nutritional status of colorectal cancer patients undergoing radio-chemotherapy in Sardjito hospital | MARTALENA PURBA | Received |
304-P | Preoperative chemoradiation in locally advanced rectal cancer: A single center experience | Liliana Oliveira | Received |
305-P | The role of adjuvant chemotherapy according to the status of surgical margin in rectal cancer patients who received preoperative chemoradiation and total mesorectal excision | SooYoon Sung | Received |
307-P | Preoperative predictors for pathologic response and prognosis of rectal cancer after neoadjuvant chemoradiation | Gyu Sang Yoo | Received |
309-P | Quality improvement in the management of rectal cancer in a large healthcare system in the United States | William Sause | Received |
311-P | Comparison between the toxicity profile of fluorouracil versus capecitabine concomitant with radiotherapy in patients with non-metastatic rectal cancer | Ahmed Nagy | Received |
313-P | Nonstandard hypofraction radiotherapy in neoadjuvant chemo-radiation therapy of locally advanced rectal cancer | Abror Abdujapparov | Received |
314-P | Prone vs supine position in patients with rectal cancer treated with volumetric arc therapy and concurrent chemotherapy | Laura Díaz | Received |
315-P | The role of palliative re-irradiation in management of rectal cancer | mohan hingorani | Received |
316-P | Is there any association of dose received by pelvic bone marrow in preoperative radiotherapy in rectal cancer with hematological toxicity of subsequent oxaliplatin-based chemotherapy? | Mateusz Spalek | Received |
317-P | A single centre experience of in-field recurrence following pre-operative radio(chemo)therapy in patients with rectal cancer | Rajarshi Roy | Received |
319-P | Long term efficacy results from the phase II CRAB trial: Neoadjuvant bevacizumab, capecitabine and radiotherapy in locally advanced rectal cancer | Vaneja Velenik | Received |
320-P | Pilot trial of YIV-906 with neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal cancer | Susan Higgins | Received |
321-P | Profile of neurotoxicity of oxaliplatin in young versus elderly patients treated for colorectal carcinoma | Hanane Fatima Zahra Aliane | Received |
322-P | First study in North Africa: Screening colorectal cancer | mazouzi chahira | Received |
20-23 June, 2018 Barcelona
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. |
||||
|